A study reveals that the travoprost intraocular implant (iDose® TR; Glaukos) delivers sustained therapeutic drug concentrations over 24 months, offering a promising long-term solution for glaucoma patients.

The study by Gabriella Szekely et al evaluated the long-term efficacy of iDose TR in treating open-angle glaucoma (OAG) and ocular hypertension (OHT). The prospective, open-label study involved 210 patients implanted with iDose TR. Aqueous humor (AH) samples were collected and analyzed at intervals over 24 months.

Results showed mean concentrations of travoprost free acid (TFA) in AH remained above the efficacious level of 95 ng/mL, with 5.0 ng/mL at 3 months and 3.3 ng/mL at 24 months. These levels exceeded the 1.78 ng/mL Cmax observed with topical travoprost. Approximately 16% of the travoprost dose remained in the implants at 24 months, indicating potential efficacy beyond 2 years.

The study concludes that iDose TR provides sustained therapeutic TFA concentrations, offering a promising long-term treatment for OAG and OHT.